---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-054869"
form_type: "8-K"
ticker: "TCMD"
cik: "0001027838"
company_name: "TACTILE SYSTEMS TECHNOLOGY INC"
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-14T23:48:09.690871+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tactile Medical Q1 revenue up 23% to $75.3M; net loss narrows to $1.8M; raises FY2026 guidance

## Summary
- Revenue $75.3M (+23% YoY); lymphedema +23%, airway clearance +22%.
- Net loss $1.8M ($0.08 per share) vs $3.0M loss in Q1 2025; gross margin 76.5% vs 74%.
- Adjusted EBITDA $3.7M vs ($0.3M) loss a year ago.
- Raised FY2026 revenue guidance to $360-368M (prev $357-365M); adj EBITDA reaffirmed at $49-51M.
- Received FDA 510(k) clearance for next-gen AffloVest; acquired LymphaTech for lymphedema diagnostics.

## SEC filing metadata
- accession: 0001104659-26-054869
- form_type: 8-K
- ticker: TCMD
- cik: 0001027838
- company_name: TACTILE SYSTEMS TECHNOLOGY INC
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1027838/000110465926054869/0001104659-26-054869-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1027838/000110465926054869/tcmd-20260504x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-054869
- JSON: https://secwatch.observer/filing/0001104659-26-054869.json
- Plain text: https://secwatch.observer/filing/0001104659-26-054869.txt

## Key facts
- Earnings Releases
  TACTILE SYSTEMS TECHNOLOGY INC reported the first quarter ended March 31, 2026 results: revenue $75.3 million, net income $1.8 million, EPS $0.08 per diluted share. Guidance raised.
  - Period: the first quarter ended March 31, 2026
  - Revenue: $75.3 million
  - Net income: $1.8 million
  - EPS: $0.08 per diluted share
  - Guidance: raised
  - Result: reported results
  source text: Total revenue in the first quarter of 2026 increased $14.0 million, or 23%, to $75.3 million, compared to $61.3 million in the first quarter of 2025. The increase in total revenue was attributable to an increase of $11.7 million, or 23%, in sales and rentals of the lymphedema product line and an increase of $2.3 million, or 22%, in sales of the airway clearance product line. Gross profit in the first quarter of 2026 increased $12.3 million, or 27%, to $57.6 million, compared to $45.3 million in the first quarter of 2025. Gross margin was 76.5% of revenue, compared to 74% of revenue in the first quarter of 2025. Operating expenses in the first quarter of 2026 increased $9.3 million, or 19%, to $59.1 million, compared to $49.9 million in the first quarter of 2025. Operating loss was $1.5 million in the first quarter of 2026, compared to $4.5 million in the first quarter of 2025. Income tax expense was $0.9 million in the first quarter of 2026, compared to an income tax benefit of $1.1 mi
  evidence_url: https://www.sec.gov/Archives/edgar/data/1027838/000110465926054869/0001104659-26-054869-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.